Symbols

Artelo Biosciences Soars 13.73% on Clinical Trial Success, Blockchain Strategy

Generated by AI AgentAinvest Pre-Market Radar

Monday, Aug 4, 2025 7:48 am ET1min read

Aime Summary

- Artelo Biosciences' stock jumped 13.73% pre-market on August 4, 2025, driven by clinical trial progress and blockchain financing.

- The UK MHRA provided favorable guidance for ART12.11's Phase 1 trial, a CBD:TMP cocrystal targeting anxiety and depression.

- A $9.475M private placement funds Artelo's Solana-based treasury strategy, positioning it as a blockchain pioneer in pharma.

Artelo Biosciences' stock surged 13.73% in pre-market trading on August 4, 2025, driven by significant developments in its clinical trials and strategic financing.

Artelo Biosciences has received favorable guidance from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its Phase 1 trial of ART12.11, a proprietary CBD:TMP cocrystalCOCP-- designed to treat anxiety and depression. This regulatory support is a crucial milestone for the company, as it paves the way for further clinical development and potential market entry.

The company has also secured a $9.475 million private placement to implement a groundbreaking Solana (SOL) treasury strategy. This strategic move not only provides Artelo with the necessary capital but also positions it as a pioneer in the pharmaceutical industry by adopting blockchain technology for financial management.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue